FindTrial
Sign In

INCB054707

DRUG8 trials

Sponsors

Incyte Corporation, Incyte Biosciences Japan GK

Conditions

Acne InversaHealthy ParticipantsHidradenitis SuppurativaKidney DiseasesNonSegmental VitiligoPrurigo NodularisRenal Insufficiency

Phase 1

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of INCB054707
CompletedNCT05068466
Incyte Biosciences Japan GKHealthy Participants
Start: 2021-10-21End: 2022-01-25Updated: 2022-09-16
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
CompletedNCT05624723
Incyte CorporationKidney Diseases, Renal Insufficiency
Start: 2023-01-12End: 2024-02-07Updated: 2024-02-13
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
CompletedNCT05624710
Incyte CorporationKidney Diseases, Renal Insufficiency
Start: 2022-12-08End: 2023-06-30Updated: 2025-08-03

Phase 2

A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
CompletedNCT03569371
Incyte CorporationHidradenitis Suppurativa
Start: 2018-07-17End: 2019-04-22Updated: 2022-09-26
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
CompletedNCT03607487
Incyte CorporationHidradenitis Suppurativa
Start: 2018-10-15End: 2019-08-13Updated: 2025-08-21
To Assess the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
CompletedNCT04476043
Incyte CorporationAcne Inversa, Hidradenitis Suppurativa
Start: 2020-08-25End: 2023-08-16Updated: 2025-08-12
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
CompletedNCT04818346
Incyte CorporationNonSegmental Vitiligo
Start: 2021-05-06End: 2023-05-24Updated: 2024-04-11
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
CompletedNCT05061693
Incyte CorporationPrurigo Nodularis
Start: 2021-11-04End: 2024-02-28Updated: 2025-07-11

Related Papers

Prevalence and Clinical Characteristics of Vitiligo-Associated Hearing Loss Among Patients in a Phase 2 Clinical Trial of Povorcitinib
Dermatology and Therapy2026-08-08
Post Hoc Subgroup and Body Region Analyses of VASI Outcomes Among Patients with Vitiligo in a Phase 2 Povorcitinib Trial.
2026-07-13
Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study.
2025-06-13
Monitoramento do Horizonte Tecnológico (MHT) de Inibidores de Janus Quinase (JAKi) para o Tratamento de Vitiligo
Epidemiologia e Serviços de Saúde2025-01-01
721 - Efficacy and safety of povorcitinib for extensive vitiligo: 52-week results from a double-blinded, placebo-controlled, dose-ranging phase 2b study
British Journal of Dermatology2024-08-015 citations
722 - Efficacy of povorcitinib for the treatment of vitiligo by patient demographics and baseline clinical characteristics: week 52 subgroup analysis from a randomized, placebo-controlled, phase 2b clinical trial
British Journal of Dermatology2024-08-011 citations
Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa
JAMA Dermatology2023-12-0614 citations
Janus kinase 1 inhibitor <scp>INCB054707</scp> for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase <scp>II</scp> studies*
British Journal of Dermatology2022-01-0381 citations